Nuvectis Pharma, Inc.

NVCT Nasdaq SEC CIK 1875558
Follow Nuvectis Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$30.1M −303% vs same quarter last year
EPS, diluted −$1.02 −131.8% vs same quarter last year
Operating cash flow −$25.3M −462.5% vs same quarter last year
Operating income −$31M −298.4% vs same quarter last year
Net income by quarter
−$6.2M
−$5.3M
−$6.3M
−$7.5M
−$7.3M
−$6.1M
−$7M
−$30.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$30M−$20M−$10M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$26.4M
FY24−$19M
FY23−$22.3M
FY22−$19.1M
FY21−$12.9M
FY20-